Valeric Acid, a Gut Microbiota Product, Penetrates to the Eye and Lowers Intraocular Pressure in Rats.
blood pressure
gut bacteria
intraocular pressure
valeric acid
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
31 Jan 2020
31 Jan 2020
Historique:
received:
17
01
2020
revised:
25
01
2020
accepted:
28
01
2020
entrez:
7
2
2020
pubmed:
7
2
2020
medline:
20
11
2020
Statut:
epublish
Résumé
Mechanisms controlling intraocular pressure (IOP) and arterial blood pressure (BP) sharesimilar mediators, including gut bacteria metabolites. Here, we investigated the effects of valericacid (VA), a short chain fatty acid produced by microbiota from undigested carbohydrates, on IOPand BP. To test if gut VA penetrates to the eye we evaluated eyes' homogenates after theadministration of D9-VA into the colon. Additionally, the following experimental series wereperformed on 16-week-old Sprague Dawley rats to analyze the influence of VA on IOP: vehicletreatment; VA treatment; VA + hydroxybutyrate - a short chain fatty acids' G protein-coupledreceptor 41/43 (GPR 41/43) blocker (ANT); hydroxybutyrate; VA + angiotensin II; angiotensin II; VAtreatment in rats with superior cervical ganglion excision and sham operated rats. D9-VA rapidlypenetrated from the colon to the eye. VA significantly decreased IOP and BP. The decrease in IOPwas gradual and lasted through the experiment. In contrast, a decrease in BP was instantaneous andlasted no longer than 10 min. Angiotensin II, ANT, and sympathetic denervation did not influencethe effect of VA on IOP. In conclusion, colon-derived VA penetrates to the eye and decreases IOP.The effect is independent from BP changes, angiotensin II, GPR41/43, and sympathetic eyeinnervation.
Identifiants
pubmed: 32024034
pii: nu12020387
doi: 10.3390/nu12020387
pmc: PMC7071253
pii:
doi:
Substances chimiques
Pentanoic Acids
0
Angiotensin II
11128-99-7
n-pentanoic acid
GZK92PJM7B
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Diabetes Res Clin Pract. 2014 Nov;106(2):173-81
pubmed: 25193333
Proc Natl Acad Sci U S A. 2013 Mar 12;110(11):4410-5
pubmed: 23401498
J Glaucoma. 2018 Sep;27(9):823-827
pubmed: 30001267
Pharmacol Res. 2018 Apr;130:172-179
pubmed: 29287686
J Ocul Pharmacol Ther. 2016 Jul-Aug;32(6):371-5
pubmed: 27092593
Biochem J. 1985 May 15;228(1):269-72
pubmed: 2988517
J Ocul Pharmacol Ther. 2018 Jan/Feb;34(1-2):61-69
pubmed: 29215951
Curr Med Res Opin. 2018 Mar;34(3):521-529
pubmed: 29219620
Proc Nutr Soc. 2010 Aug;69(3):434-41
pubmed: 20540826
Aliment Pharmacol Ther. 2018 Jul;48(1):15-34
pubmed: 29722430
Proc Natl Acad Sci U S A. 2011 May 10;108(19):8030-5
pubmed: 21518883
Adv Immunol. 2014;121:91-119
pubmed: 24388214
Gut. 2019 Aug;68(8):1417-1429
pubmed: 30782617
Curr Hypertens Rep. 2017 Apr;19(4):25
pubmed: 28315048
Mol Pharmacol. 2016 Mar;89(3):388-98
pubmed: 26719580
Gut. 2018 Sep;67(9):1716-1725
pubmed: 29934437
J Hypertens. 2017 Sep;35(9):1899-1908
pubmed: 28509726